Navigation Links
Engineered cells could usher in programmable cell therapies

Boston, MA - In work that could jumpstart the promising field of cell therapy, in which cells are transplanted into the body to treat a variety of diseases and tissue defects, researchers at Brigham and Women's Hospital (BWH) have engineered cells that could solve one of the key challenges associated with the procedure: control of the cells and their microenvironment following transplantation.

In the work, reported in the journal Biomaterials on January 26, the team reports creating tiny internal depots within human mesenchymal adult stem cells, which among other functions are key to the generation of several tissues. These depots can slowly release a variety of agents to influence the behavior of not only the cells containing the depots, but also those close to them and even much farther away. The team demonstrated this by prompting mesenchymal stem cells to differentiate into the cells that make bone.

"This work could allow programmable cell therapies where the cell or the agent is the therapeutic," says Jeffrey Karp, leader of the work and co-director of the Center for Regenerative Therapeutics (ReGen Rx) at BWH. "For example, depots containing specific agents could enhance cell survival or expression of a particular growth factor. Cells could also be used as a delivery vehicle to shuttle drugs to target tissues that may be useful to accelerate tissue regeneration, or to deliver chemotherapeutics to tumors while minimizing systemic side effects."

Toward Cell Therapy

"Ten to fifteen years from now, people will visit cell infusion centers to receive routine therapy for multiple diseases and tissue defects," predicts Karp, who also holds appointments through Harvard Medical School, Harvard Stem Cell Institute, and the Harvard-MIT Division of Health Sciences and Technology (HST). For example, a person who has had a heart attack could be infused with cells that could help stimulate regeneration of new heart cells to replace those that have died and prevent eventual heart failure.

Today, however, there is only one cell therapy that has saved tens of thousands of lives: bone marrow transplantation. In this procedure healthy blood stem cells home in to the bone marrow to regenerate the blood system of cancer patients following bone marrow ablation through chemotherapy or radiation.

One of the reasons for the lack of success of other cell therapies is the inability to control the cells and the host's response following transplantation, says Karp. "We can exhibit exquisite control over cells in a [laboratory] dishwe can get them to do whatever we want. But when we transplant them into the body, their fate and function are at the mercy of the biological milieu. We typically lose complete control and this prevents us from achieving the promise of cell therapy."

There are ways to get around this problem, but they have limitations. For example, cells can be put on a scaffold or biomaterial that releases drugs or other agents that affect their behavior. The cells, however, have to stay in close proximity to the material to be impacted by the agents. Cells can also be genetically modified with viruses to produce agents that will influence their behavior, but this has potential safety concerns.

Natural Inspiration

The Karp team was inspired by the natural ability of many proteins and other agents to be transported in and out of cells. They already knew that cells could internalize the tiny synthetic particles used in the controlled delivery of drugscould these particles be used in cell therapy?

To find out, the researchers developed biodegradable particles about ten times smaller than a mesenchymal stem cell (MSC). They loaded these particles with a dye, placed them near living MSCs, and found that the cells did indeed internalize them without immediately spitting them out. "Initially, this was a major challenge," comments James A. Ankrum, co-first author on the paper and an HST graduate student. "The particles needed to be small enough for the cells to internalize, yet large enough to prevent being shed by the cell." The dye was observed to seep from the tiny particle depots to the outside of the cell through the cell membrane over a period of several days.

Next, they replaced the dye with an agent known to spur MSCs to differentiate into osteoblasts, the cells that make bone. They found that not only did MSCs containing the depots differentiate into osteoblasts, but so did MSCs without depots that were nearby and even much further away. "We demonstrated that the fate of particle-carrying cells could be controlled, as well as the fates of neighboring and distant cells," says Debanjan Sarkar, co-first author of the paper and now a professor at the University of Buffalo.

Additional authors are Grace S. L. Teo of HST and Christopher V. Carman of Beth Israel Deaconess Hospital.

To date the team has demonstrated the engineered cells in laboratory systems designed to mimic the body. They are in the process of translating the work to animals. "If it works in vivo, it could have a significant impact globally on cell therapy," says Karp, whose team has filed for a patent on the work.


Contact: Holly Brown-Ayers
Brigham and Women's Hospital

Related biology technology :

1. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
2. Gene-engineered flies are pest solution
3. MIT, BU team combats antibiotic resistance with engineered viruses
4. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
5. Genetically engineered bacteria compute the route
6. First genetically engineered malaria vaccine to enter human trials
7. Pioneering research succeeds in producing industrially vital chemical through engineered bacteria
8. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
9. Engineered pea seeds protect against parasites
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI
11. Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
Post Your Comments:
Related Image:
Engineered cells could usher in programmable cell therapies
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):